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ABSTRACT
Objective To identify clusters of peripheral involvement 
according to the specific location of peripheral 
manifestations (ie, arthritis, enthesitis and dactylitis) 
in patients with spondyloarthritis (SpA) including 
psoriatic arthritis (PsA), and to evaluate whether these 
clusters correspond with the clinical diagnosis of a 
rheumatologist.
Methods Cross- sectional study with 24 participating 
countries. Consecutive patients diagnosed by their 
rheumatologist as PsA, axial SpA or peripheral SpA were 
enrolled. Four different cluster analyses were conducted: 
one using information on the specific location from all 
the peripheral manifestations, and a cluster analysis 
for each peripheral manifestation, separately. Multiple 
correspondence analyses and k- means clustering methods 
were used. Distribution of peripheral manifestations and 
clinical characteristics were compared across the different 
clusters.
Results The different cluster analyses performed in 
the 4465 patients clearly distinguished a predominantly 
axial phenotype (cluster 1) and a predominantly 
peripheral phenotype (cluster 2). In the predominantly 
axial phenotype, hip involvement and lower limb 
large joint arthritis, heel enthesitis and lack of 
dactylitis were more prevalent. In the predominantly 
peripheral phenotype, different subgroups were 
distinguished based on the type and location of 
peripheral involvement: a predominantly involvement 
of upper versus lower limbs joints, a predominantly 
axial enthesitis versus peripheral enthesitis, and 
predominantly finger versus toe involvement in 
dactylitis. A poor agreement between the clusters and 
the rheumatologist‘s diagnosis as well as with the 
classification criteria was found.
Conclusion These results suggest the presence 
of two main phenotypes (predominantly axial and 
predominantly peripheral) based on the presence and 
location of the peripheral manifestations.
Key messages
What is already known about this subject?
 ► Peripheral manifestations can occur across the en-
tire spectrum of spondyloarthritis (SpA) and they 
play a key role in deciding about an exact diagnosis 
in patients with SpA.
 ► Recently, the worldwide Assessment of 
Spondyloarthritis international Society- peripheral 
SpA (PerSpA) study demonstrated that all different 
peripheral features can be found in all subtypes of 
SpA (including psoriatic arthritis (PsA)), and that dif-
ferences are quantitative rather than qualitative.
 ► However, these differences in frequency and distri-
bution may influence the clinical diagnosis by the 
rheumatologist, based on their own experience or 
knowledge.
What does this study add?
 ► These results distinguish two main phenotypes (a 
predominantly axial and a predominantly peripheral 
phenotype) on the basis of the peripheral manifes-
tations, which fitted a clinical diagnosis of axial SpA 
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INTRODUCTION
Spondyloarthritis (SpA) represents a chronic inflamma-
tory disease that typically affects the axial skeleton and 
sacroiliac joints.1 Nevertheless, SpA also often affects the 
appendicular skeleton with peripheral manifestations 
such as arthritis, enthesitis and dactylitis. In 2009, the 
Assessment of Spondyloarthritis international Society 
(ASAS) introduced the concept of axial (axSpA) and 
peripheral SpA (pSpA) for patients with predominant 
axial or peripheral symptoms, respectively.2 In parallel, 
the CASPAR Study Group proposed specific criteria for 
the classification of psoriatic arthritis (PsA).3 Whether 
PsA can be considered part of SpA or as a separate entity 
has been a matter of debate in the last few years, since 
many similarities and differences have been described 
between these two diseases: first, inflammatory back pain 
(IBP) and radiographic sacroiliitis can appear in both 
groups.4 Second, both patients with PsA and SpA exhibit 
peripheral musculoskeletal manifestations, but a higher 
prevalence of such manifestations (especially dactylitis) 
and a lower prevalence of HLA- B27 positivity have been 
reported in patients with PsA.5 Moreover, the typical 
clinical presentation of articular involvement in pSpA 
has been described as an asymmetric, monoarticular or 
oligoarticular inflammatory arthritis that involves the 
lower limbs more frequently than the upper limbs,6 
while a variety of arthritis patterns are seen in PsA. It is 
still under debate whether polyarticular inflammatory 
arthritis, which often involves the distal interphalangeal 
joints (a typical clinical presentation in patients with PsA) 
should be seen as part of pSpA.7
One major concern about studies that compare these 
subtypes is the fact that they usually differentiate patients 
either as SpA or PsA depending on the rheumatolo-
gist’s opinion, which in many cases is influenced by their 
education and background in the field. As an example, a 
patient with radiographic sacroiliitis and cutaneous psori-
asis may be diagnosed as ‘axSpA with psoriasis’ or ‘axial 
PsA’ depending on the rheumatologist’s preferences.
Recently, the worldwide ASAS- PerSpA study demon-
strated that all different peripheral features can be found 
in all subtypes of SpA (including PsA), and that differ-
ences are quantitative rather than qualitative.8 However, 
as explained above, these differences in frequency and 
distribution may influence the clinical diagnosis by the 
rheumatologist, based on their own experience or knowl-
edge. This clinical reasoning results in the diagnosis of 
either axSpA, pSpA or PsA. The use of exploratory anal-
ysis for grouping patients (clusters) from the whole spec-
trum of SpA may be useful to group patients according 
to their clinical characteristics, and to confirm whether 
certain clusters are more frequent in patients with a spec-
ified diagnosis (either axSpA, pSpA or PsA) according to 
the rheumatologist. Clustering analysis represents a class 
of unsupervised exploratory analytical techniques, which 
aims to identify homogeneous groups of cases without 
taking prior information about the group of cluster or 
membership into account. In this sense, this technique 
may be especially valuable in the identification of clusters 
with regard to the peripheral involvement in the whole 
spectrum of SpA.
In this study, we conducted an unsupervised analysis 
with the aim to identify clusters of peripheral involvement 
based on the specific location of these manifestations 
in the whole spectrum of SpA, and to evaluate whether 
these clusters are in agreement with the rheumatologist’s 
diagnosis (ie, axSpA, pSpA and PsA) and classification 
criteria.
METHODS
Patients and study design
The ASAS- PerSpA is an observational, cross- sectional, 
multicentre and international study with 24 participating 
countries and 68 centres from four continents (Africa, 
America, Asia and Europe). Consecutive adult patients 
(eg, at least 18 years old) with a diagnosis of SpA (either 
axSpA, pSpA or PsA) according to clinical diagnosis of 
their rheumatologist and who were able to understand 
and complete questionnaires were included. The ASAS- 
PerSpA study has been previously described in detail.8 
Written informed consent was obtained from all subjects 
before enrolment.
Collected data
Five different categories of data were collected:
1. Demographics: age, sex, smoking and alcohol intake.
2. Disease characteristics: the investigators were asked 
to name the diagnosis that in their opinion best de-
scribed the disease of the patient. They could choose 
from the following list: axSpA, PsA, pSpA, inflamma-
tory bowel disease (IBD)- SpA, ReA, Juv- SpA, or they 
could name another disease. In addition, information 
about HLA- B27 status, axial involvement according 
to the rheumatologist, uveitis, psoriasis and IBD were 
collected. The individual items from the ASAS axSpA, 
ASAS pSpA and CASPAR criteria were collected.2 3 
However, pSpA ASAS criteria were evaluated in two 
ways: (a) following the strict rules considering IBP as 
excluding item for ASAS pSpA criteria (‘strict crite-
ria’) and (b) ignoring IBP as excluding item (‘non- 
strict criteria’). The use of conventional synthetic and 
Key messages
How might this impact on clinical practice or future 
developments?
 ► The often- artificial difference between axSpA and PerSpA therefore 
continues to make sense, although an important overlap of pe-
ripheral manifestations was found across the different underlying 
entities.
 ► These results also confirm the variability of making a diagno-
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biological disease- modifying antirheumatic drugs was 
also collected.
3. Peripheral musculoskeletal manifestations: history or cur-
rent presence of specific locations of arthritis (includ-
ing hip and shoulder involvement), enthesitis and 
dactylitis that the patient has ever suffered from in the 
course of their disease were collected.
4. Disease activity and disease burden: current disease activ-
ity was measured by the Bath Ankylosing Spondylitis 
Disease Activity Index (BASDAI),9 and the Ankylosing 
Spondylitis Disease Activity Score was calculated with 
the C reactive protein (ASDAS- CRP).10 The Bath 
Ankylosing Spondylitis Functional Index (BASFI) and 
the ASAS Health Index (ASAS- HI) were used to eval-
uate physical function and functioning and health, 
respectively.11 12 Finally, the self- reported Fibromyalgia 
Rapid Screening Tool (FiRST) was applied to deter-
mine the presence of concomitant fibromyalgia.13
All information was obtained by a study investigator or 
research nurse during a face- to- face interview at a study 
visit, which included a review of the medical record. A 
centralised electronic case report form was used.
Statistical analysis
Unsupervised statistical learning methods were used to 
discover inherent but hidden patterns in the data. More 
specifically, for peripheral musculoskeletal manifestations 
(ie, arthritis, enthesitis and dactylitis), we aimed to split 
the observations into a number of subsets determined by 
the specific location of these manifestations at any time 
during the course of the disease. Four different cluster 
analyses were conducted: the first one using information 
from all peripheral musculoskeletal manifestations (ie, 
arthritis, enthesitis and dactylitis) with the aim to eval-
uate the number of patterns taking into account overall 
peripheral manifestations. After that, we conducted one 
cluster analysis for each peripheral manifestation (ie, 
one analysis for arthritis; a second analysis for enthesitis 
and a third analysis for dactylitis) to evaluate whether the 
patterns are different depending on the specific mani-
festation.
First, for each location of each peripheral manifesta-
tion, a variable was created to reflect the presence (=1) 
or absence of current or past involvement (=0); locations 
with missing information were considered as absence 
of involvement. Multiple correspondence analyses 
(MCA) were used to analyse the patterns of relationships 
between those variables, with plots allowing visualisation 
of the distance between the categories, and thus facili-
tating our interpretation of the data. A final character-
istic of an MCA is that it is weighted, with each variable 
being allocated a weight that increases with its scarcity, 
in order to make any differences relating to the rarest 
and most distinctive modalities especially visible. Statisti-
cally comparable individuals (and characteristics shared 
by these individuals) are represented on these graphs as 
points which tend to group together, while dissimilarity, 
on the other hand, results in distance.
Then, clustering was conducted using an iterative parti-
tioning k- means method. The optimal number of clusters 
was estimated using the ‘NbClust’ package, which provides 
30 indices and proposes the best clustering scheme from 
the different results obtained by varying all combinations 
of the number of clusters, distance measures and clus-
tering methods.14 The NbClust provides the number of 
clusters proposed by all the indices and proposes the best 
number of clusters according to the majority rule.
After the extraction of the clusters, the distribution 
of the different locations of peripheral manifestations 
across groups was described. Sociodemographic and 
clinical characteristics, rheumatologist’s diagnosis, classi-
fication criteria (including ‘strict’ and ‘non- strict’ pSpA 
ASAS criteria), disease activity and disease burden were 
compared across the different clusters using the χ2 test or 
the exact Fisher’s test for qualitative variables, and anal-
ysis of variance or Kruskal- Wallis tests for continuous vari-
ables depending on the normality of the variables. This 
process was done first for all peripheral manifestations, 
and thereafter for each of the peripheral manifestations 
separately (ie, arthritis, enthesitis and dactylitis).
Data were processed and analysed using RStudio 
V.1.0.143.
RESULTS
Cluster analysis on all peripheral musculoskeletal 
manifestations together
All the patients participating in the PerSpA were 
included in this analysis (n=4465). MCA using informa-
tion concerning the specific location of all peripheral 
musculoskeletal manifestations (ie, arthritis, enthesitis 
and dactylitis) in the overall population is represented 
in online supplemental figure S1. The cloud of points 
(ie, variables) showed a group of variables reflecting the 
absence of any peripheral manifestation on the intersec-
tion of the two dimensions. Hip involvement was posi-
tioned very close (ie, associated) to this group, as well 
as knee, shoulder and ankle involvement. Interestingly, 
plantar fascia and Achilles tendon involvement was also 
positioned close to the group of variables which repre-
senting the absence of any peripheral manifestation. 
Variables representing toes and fingers involvement 
(either as arthritis or dactylitis) formed a conglomerate 
on the right bottom of the figure. Finally, a wide variety of 
enthesitis locations represented another conglomerate 
on the right top of the figure.
The clustering algorithm and the analysis of the 
optimal number of clusters led to the classification of the 
4465 patients into two groups (with 3984 and 481 patients 
each). The distribution of peripheral involvement across 
the two clusters is represented in figure 1. Overall, cluster 
1 (that we decided to call ‘predominantly axial’ cluster) 
showed a low prevalence of all the peripheral manifes-
tations in comparison with cluster 2 (that we decided to 
call ‘predominantly peripheral’); however, when periph-
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axial’ cluster, it was mostly represented by hip, knee and 
ankle arthritis, as well as Achilles tendon and plantar 
fascia enthesitis. The ‘predominantly peripheral’ cluster 
showed a high prevalence of all the peripheral manifesta-
tions, especially arthritis.
Sociodemographic data, clinical characteristics, 
disease activity and disease burden across the clusters are 
represented in table 1. Patients from the ‘predominantly 
axial’ cluster (cluster 1) showed a higher prevalence of 
males (63.1% vs 43.5%), HLA- B27 positivity (68.6% vs 
37.8%), axial involvement according to the rheumatol-
ogist (79.7% vs 52.4%) and uveitis (17.9% vs 9.8%). In 
addition, patients from the ‘predominantly axial’ cluster 
had more frequently a diagnosis of axSpA according 
to the rheumatologist (65.7% vs 21.2%), fulfilled more 
frequently axial ASAS criteria, and showed a lower 
burden of disease measured by the BASFI (2.9 vs 4.0) and 
the ASAS- HI (4.5 vs 4.9). On the other hand, patients 
from the ‘predominantly peripheral’ cluster (cluster 2) 
showed, in comparison with the other cluster, a higher 
prevalence of psoriasis (63.0% vs 24.5%), a higher 
disease activity (BASDAI 4.9 vs 3.7 and ASDAS 2.9 vs 2.5, 
respectively), a more frequent diagnosis of PsA (61.3% 
vs 18.5%), and they fulfilled more frequently the ‘strict’ 
peripheral ASAS (25.8% vs 10.8%), the ‘non- strict’ 
peripheral ASAS (46.8% vs 26.3%) and the CASPAR 
criteria (56.8% vs 19.3%).
Cluster analysis on arthritis only
Online supplemental figure S2 represents the MCA 
using information only concerning the specific loca-
tion of arthritis. The cloud of variables showed, simi-
larly to the previous analysis, a group of variables coded 
0 (ie, ‘absence’ of arthritis) on the intersection of the 
two dimensions. Hip involvement was positioned very 
close to this group, as well as knee, shoulder and ankle 
arthritis. Interestingly, two additional conglomerates of 
variables were found: one reflecting hand involvement 
(ie, metacarpophalangeal, and finger proximal inter-
phalangeal and distal interphalangeal involvement of the 
fingers) and one reflecting feet involvement (ie, metatar-
sophalangeal, and toe proximal and distal interphalan-
geal involvement).
A total of 3 clusters were found, with 3839, 115 and 520 
patients respectively. One cluster (1A) showed a lower 
prevalence of peripheral joint involvement in general 
than the other two clusters (figure 2A); however, in case 
of arthritis, it was more frequently located on the lower 
limbs. The other two clusters (2A and 3A) showed a high 
prevalence of arthritis, although predominantly in the 
lower limbs versus in the upper limbs, respectively.
With regard to other clinical data (table 2), cluster 1A 
showed a higher prevalence of males (63.9% vs 51.3% 
vs 41.5% for A1, A2 and A3, respectively), HLA- B27 
positivity (79.8% vs 48.2% vs 34.8%), axial involvement 
according to the rheumatologist (80.9% vs 54.8% vs 
51.5%), a lower presence of psoriasis (23.2% vs 67.8% vs 
59.6%), and a more frequent diagnosis of axSpA (67.2% 
vs 20.9% vs 23.7%) and fulfilment of the axial ASAS 
criteria (70.6% vs 48.7% vs 37.1%) in comparison with 
clusters 2A and 3A, respectively. Conversely, clusters 2A 
and 3A showed a higher prevalence of enthesitis (64.3% 
vs 52.9% vs 42.7%, for A2 vs A3 vs A1, respectively) and 
dactylitis (47.8% vs 34.4% vs 11.8%) in comparison with 
cluster 1A, a more frequent diagnosis of PsA (61.7% vs 
58.5% vs 17.2%), fulfilment of the CASPAR (63.5% vs 
52.9% vs 18.1%), pSpA ‘strict’ criteria (22.6% vs 26.2% vs 
10.2%) and pSpA ‘non- strict’ criteria (40.9% vs 50.4% vs 
25.1%). Interestingly, these two clusters showed a higher 
burden of disease (BASFI 4.1 vs 4.0 vs 2.8 and ASAS- HI 
9.0 vs 8.2 vs 6.3).
The most important differences found between clus-
ters 2A and 3A were the prevalence of uveitis (15.7% vs 
8.7%) and IBD (3.5% vs 6.7%), respectively.
Figure 1 Distribution of the location of peripheral involvement across clusters with regard to the all the peripheral 
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Cluster analysis on enthesitis only
MCA using information concerning the specific location 
of enthesitis is represented in online supplemental figure 
S3. Achilles tendon and plantar fascia involvement were 
positioned very close to the group of variables reflecting 
the absence of enthesitis. Interestingly, two other groups 
of variables were found: one group including axial loca-
tions (ie, chondrosternal, iliac spine, cervical and lumbar 
processes) and a second group including peripheral loca-
tions (femur and humeral condyles, tibial tubercle and 
the quadriceps patellar insertion). Three clusters were 
found with regard to the enthesitis location (with 4089, 
Table 1 Sociodemographic data, clinical characteristics, disease activity and disease burden across the two clusters with 
regard to the location of all the peripheral musculoskeletal manifestations
Cluster 1 (predominant axial 
phenotype) N=3984
Cluster 2 (predominant peripheral 
phenotype) N=481
Rheumatologist’s diagnosis
  Axial spondyloarthritis 2617 (65.7%) 102 (21.2%)
  Peripheral spondyloarthritis 380 (9.5%) 53 (11.0%)
  Psoriatic arthritis 738 (18.5%) 295 (61.3%)
  ReA or IBD- SpA 147 (3.7%) 21 (4.4%)
  Juv- SpA or others 102 (2.6%) 10 (2.1%)
Classification criteria
  ASAS axial criteria 2758 (69.2%) 195 (40.5%)
  ASAS peripheral ‘strict’ criteria 429 (10.8%) 124 (25.8%)
  ASAS peripheral ‘non- strict’ criteria 1046 (26.3%) 225 (46.8%)
  CASPAR criteria 770 (19.3%) 273 (56.8%)
Demographic characteristics
  Age, mean (SD) 43.8 (13.9) 50.2 (13.4)
  Disease duration 14.1 (11.2) 16.3 (11.8)
  Sex (male) 2515 (63.1%) 209 (43.5%)
  Ever smoker 1695/3980 (42.6%) 205 (42.6%)
  Ever alcohol 1619/3981 (40.7%) 193 (40.1%)
Phenotype
  HLA- B27+ 1973/2874 (68.6%) 93/246 (37.8%)
  Axial involvement (ever) 3176 (79.7%) 252 (52.4%)
  Arthritis (ever) 2061 (51.7%) 480 (99.8%)
  Enthesitis (ever) 1692 (42.5%) 292 (60.7%)
  Dactylitis (ever) 474 (11.9%) 211 (43.9%)
  Uveitis (ever) 715 (17.9%) 47 (9.8%)
  Psoriasis (ever) 975 (24.5%) 303 (63.0%)
  IBD (ever) 252 (6.3%) 29 (6.0%)
Treatment
  csDMARDs (ever) 2534 (63.6%) 453 (94.2%)
  bDMARDs (ever) 2342 (58.8%) 305 (63.4%)
Disease activity and severity
  BASDAI, mean (SD) 3.7 (2.4) 4.9 (2.6)
  ASDAS- CRP, mean (SD) 2.5 (1.1) 2.9 (1.2)
  BASFI, mean (SD) 2.9 (2.6) 4.0 (2.9)
  ASAS- HI, mean (SD) 6.3 (4.5) 8.6 (4.9)
  Concomitant fibromyalgia* 620/3671 (16.9%) 155/456 (34.0%)
All results are presented as mean and SD and percentages for continuous and categorical variables, respectively.
*Presence of Fibromyalgia defined by the fulfilment of the Fibromyalgia Rapid Screen Tool (FiRST).13
ASAS- HI, ASAS Health Index; ASDAS- CRP, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Disease Activity Index; 
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256 and 120 patients, respectively). Cluster 1B showed 
a very low prevalence of enthesitis (figure 2B) but, if 
present, they were more frequently located at the Achilles 
tendon and plantar fascia (ie, heel enthesitis). Clusters 
2B and 3B showed a high prevalence of enthesitis, with a 
predominant involvement of axial locations in cluster 2B 
and peripheral locations in cluster 3B.
Clinical data showed some similarities between clus-
ters 1B and 2B, and differences with regard to cluster 
3B (table 3), such as a higher prevalence of HLA- B27+ 
(66.7% vs 61.5% vs 45.5% for B1 vs B2 vs B3, respec-
tively), axial involvement (76.4% vs 86.3% vs 68.3%), 
uveitis (17.2% vs 18.8% vs 9.2%) and a more frequent 
diagnosis of axSpA according to the rheumatologist 
Figure 2 Distribution of the location of peripheral involvement across clusters with regard to the arthritis (A), enthesitis 
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(61.4% vs 64.1% vs 37.5%). In addition, cluster number 
1B showed the lowest disease activity (BASDAI 3.7 vs 
5.0 vs 5.3 and ASDAS 2.5 vs 3.1 vs 3.1) and the mildest 
burden of disease (BASFI 2.9 vs 4.2 vs 4.3 and ASAS- HI 
6.3 vs 8.9 vs 10.4). On the other hand, cluster number 
3B (the cluster with predominant peripheral locations), 
showed a higher prevalence of arthritis and dactylitis in 
comparison with clusters 1B and 2B, psoriasis (48.3% 
vs 28.4% vs 23.4%, respectively) and diagnosis of PsA 
(40.8% vs 21.5% vs 22.7%).
Cluster analysis on dactylitis only
MCA using information about dactylitis (online supple-
mental figure S4) exhibited three groups of variables: one 
Table 2 Sociodemographic data, clinical characteristics, disease activity and disease burden across the three clusters with 








  Axial spondyloarthritis 2572 (67.2%) 24 (20.9%) 123 (23.7%)
  Peripheral spondyloarthritis 362 (9.5%) 11 (9.7%) 60 (11.5%)
  Psoriatic arthritis 658 (17.2%) 71 (61.7%) 304 (58.5%)
  ReA or IBD- SpA 142 (3.7%) 2 (1.7%) 24 (4.6%)
  Juv- SpA or others 96 (2.5%) 7 (6.0%) 9 (1.7%)
Classification criteria
  ASAS axial criteria 2704 (70.6%) 56 (48.7%) 193 (37.1%)
  ASAS peripheral strict criteria 391 (10.2%) 26 (22.6%) 136 (26.2%)
  ASAS peripheral ‘non- strict’ 962 (25.1%) 47 (40.9%) 262 (50.4%)
  CASPAR criteria 695 (18.1%) 73 (63.5%) 275 (52.9%)
Demographic characteristics
  Age, mean (SD) 43.4 (13.8) 50.4 (13.4) 51.2 (13.3)
  Disease duration 13.9 (11.1) 18.7 (12.6) 16.4 (12.0)
  Sex (male) 2449 (63.9%) 59 (51.3%) 216 (41.5%)
  Ever smoker 1618/3826 (42.3%) 48 (41.7%) 234 (45.0%)
  Ever alcohol 1561/3827 (40.8%) 51 (44.3%) 200 (38.5%)
Phenotype
  HLA- B27+ 1941/2782 (79.8%) 27/56 (48.2%) 98/282 (34.8%)
  Axial involvement (ever) 3097 (80.9%) 63 (54.8%) 268 (51.5%)
  Enthesitis (ever) 1635 (42.7%) 74 (64.3%) 275 (52.9%)
  Dactylitis (ever) 451 (11.8%) 55 (47.8%) 179 (34.4%)
  Uveitis (ever) 699 (18.3%) 18 (15.7%) 45 (8.7%)
  Psoriasis (ever) 890 (23.2%) 78 (67.8%) 310 (59.6%)
  IBD (ever) 242 (6.3%) 4 (3.5%) 35 (6.7%)
Treatment
  csDMARDs (ever) 2393 (62.5%) 110 (95.7%) 484 (93.1%)
  bDMARDs (ever) 2250 (58.7%) 80 (69.6%) 317 (61.0%)
Disease activity and severity
  BASDAI, mean (SD) 3.7 (2.4) 4.7 (2.6) 4.9 (2.6)
  ASDAS- CRP, mean (SD) 2.5 (1.1) 2.9 (1.3) 2.8 (1.2)
  BASFI, mean (SD) 2.8 (2.6) 4.1 (2.9) 4.0 (2.9)
  ASAS- HI, mean (SD) 6.3 (4.5) 9.0 (5.0) 8.2 (4.7)
  Concomitant fibromyalgia* 576/3523 (16.3%) 37/107 (34.6%) 162/497 (32.6%)
All results are presented as mean and SD and percentages for continuous and categorical variables, respectively.
*Presence of fibromyalgia defined by the fulfilment of the Fibromyalgia Rapid Screen Tool (FiRST).13
ASAS- HI, ASAS Health Index; ASDAS- CRP, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Disease Activity Index; 
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group reflecting the absence of dactylitis, a second group 
with the variables referring to the fingers, and a third one 
with the toes. In this line, we found three clusters (4291, 
140 and 34 patients, respectively) which showed a very low 
prevalence of dactylitis, a predominantly toes and predomi-
nantly fingers involvement, respectively (figure 2C). Cluster 
1C showed, in comparison with clusters 2C and 3C, a higher 
prevalence of HLA- B27 positivity (66.6% vs 52.5% vs 50.0%), 
axial involvement (77.7% vs 54.3% vs 52.9%), a diagnosis of 
axial SpA according to the rheumatologist (62.6% vs 20.0% 
vs 11.8%) and a lower prevalence of psoriasis (26.9% vs 
68.6% vs 79.4%) (table 4). On the other hand, clusters 2C 
Table 3 Sociodemographic data, clinical characteristics, disease activity and disease burden across the three clusters with 








  Axial spondyloarthritis 2510 (61.4%) 164 (64.1%) 45 (37.5%)
  Peripheral spondyloarthritis 392 (9.6%) 23 (9.0%) 18 (15.0%)
  Psoriatic arthritis 929 (22.7%) 55 (21.5%) 49 (40.8%)
  ReA or IBD- SpA 157 (3.8%) 8 (3.1%) 3 (2.5%)
  Juv- SpA or others 101 (2.5%) 6 (2.3%) 5 (4.2%)
Classification criteria
  ASAS axial criteria 2683 (65.6%) 196 (76.6%) 74 (61.7%)
  ASAS peripheral ‘strict’ criteria 492 (12.0%) 34 (13.3%) 29 (24.2%)
  ASAS peripheral ‘non- strict’ 
criteria
1176 (28.8%) 55 (21.5%) 40 (33.3%)
  CASPAR criteria 932 (22.8%) 57 (22.3%) 54 (45.0%)
Demographic characteristics
  Age 44.5 (14.0) 42.8 (12.5) 45.3 (13.9)
  Disease duration 14.3 (11.4) 14.6 (10.6) 14.0 (11.6)
  Sex (male) 2532 (61.9%) 144 (56.2%) 48 (40.0%)
  Ever smoker 1752 (42.9%) 104 (40.6%) 44 (36.7%)
  Ever alcohol 1682 (41.2%) 93 (36.3%) 37 (30.8%)
Phenotype
  HLA- B27+ 1932/2885 (66.7%) 104/169 (61.5%) 30/66 (45.5%)
  Axial involvement (ever) 3125 (76.4%) 221 (86.3%) 82 (68.3%)
  Arthritis (ever) 2267 (55.4%) 177 (69.1%) 97 (80.8%)
  Dactylitis (ever) 600 (14.7%) 57 (22.3%) 28 (23.3%)
  Uveitis (ever) 703 (17.2%) 48 (18.8%) 11 (9.2%)
  Psoriasis (ever) 1160 (28.4%) 60 (23.4%) 58 (48.3%)
  IBD (ever) 261 (6.4%) 15 (5.9%) 5 (4.2%)
Treatment
  csDMARDs (ever) 2665 (65.2%) 210 (82.0%) 112 (93.3%)
  bDMARDs (ever) 2408 (58.9%) 159 (62.1%) 80 (66.7%)
Disease activity and severity
  BASDAI 3.7 (2.4) 5.0 (2.6) 5.3 (2.4)
  ASDAS- CRP 2.5 (1.1) 3.1 (1.2) 3.1 (1.1)
  BASFI 2.9 (2.6) 4.2 (2.9) 4.3 (2.8)
  ASAS- HI 6.3 (4.5) 8.9 (4.4) 10.4 (4.2)
  Concomitant fibromyalgia 657/3785 (17.4%) 73/233 (31.1%) 45 (41.3%)
All results are presented as mean and SD and percentages for continuous and categorical variables, respectively.
*Presence of Fibromyalgia defined by the fulfilment of the Fibromyalgia Rapid Screen Tool (FiRST).13
ASAS- HI, ASAS Health Index; ASDAS- CRP, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Disease Activity Index; 
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and 3C showed a higher prevalence of peripheral involve-
ment (ie, arthritis and enthesitis) and a diagnosis of PsA 
(65.7% vs 52.9% vs 21.5%) than cluster 1C.
DISCUSSION
In this analysis conducted in the worldwide ASAS- 
PerSpA study,8 we tried to define groups of peripheral 
manifestations (ie, clusters), in a population of patients 
with SpA. By classifying the patients by their clinical 
presentation, a predominantly axial and a predomi-
nantly peripheral cluster were identified, which were 
mor frequently recognised by physicians as axSpA and 
as pSpA or PsA, respectively. Peripheral features were 
found in all the groups, but differences were quantitative 
Table 4 Sociodemographic data, clinical characteristics, disease activity and disease burden across the three clusters with 








  Axial spondyloarthritis 2687 (62.6%) 28 (20.0%) 4 (11.8%)
  Peripheral spondyloarthritis 408 (9.5%) 15 (10.7%) 10 (29.4%)
  Psoriatic arthritis 923 (21.5%) 92 (65.7%) 18 (52.9%)
  ReA or IBD- SpA 165 (3.8%) 2 (1.4%) 1 (2.9%)
  Juv- SpA or others 108 (2.5%) 3 (2.1%) 1 (2.9%)
Classification criteria
  ASAS axial criteria 2885 (67.2%) 56 (40.0%) 12 (35.3%)
  ASAS peripheral ‘strict’ criteria 497 (11.6%) 46 (32.9%) 12 (35.3%)
  ASAS peripheral ‘non- strict’ criteria 1171 (27.3%) 82 (58.6%) 18 (52.9%)
  CASPAR criteria 916 (21.3%) 99 (70.7%) 28 (82.4%)
Demographic characteristics
  Age 44.4 (13.9) 45.9 (13.8) 51.7 (13.9)
  Disease duration 14.3 (11.3) 14.7 (11.7) 17.7 (11.3)
  Sex (male) 2634 (61.4%) 72 (51.4%) 18 (52.9%)
  Ever smoker 1834/4287 (42.8%) 51 (36.4%) 15 (44.1%)
  Ever alcohol 1733 (40.4%) 55 (39.3%) 24 (70.6%)
Phenotype
  HLA- B27+ 2018/3028 (66.6%) 42/80 (52.5%) 6/12 (50.0%)
  Axial involvement (ever) 3334 (77.7%) 76 (54.3%) 18 (52.9%)
  Arthritis (ever) 2370 (55.2%) 139 (99.3%) 32 (94.1%)
  Enthesitis (ever) 1873 (43.6%) 93 (66.4%) 18 (52.9%)
  Uveitis (ever) 744 (17.3%) 13 (9.3%) 5 (14.7%)
  Psoriasis (ever) 1155 (26.9%) 96 (68.6%) 27 (79.4%)
  IBD (ever) 275 (6.4%) 4 (2.9%) 2 (5.9%)
Treatment
  csDMARDs (ever) 2822 (65.8%) 135 (96.4%) 30 (88.2%)
  bDMARDs (ever) 2527 (58.9%) 91 (65.0%) 29 (85.3%)
Disease activity and severity
  BASDAI 3.8 (2.4) 4.1 (2.6) 3.9 (2.3)
  ASDAS- CRP 2.5 (1.1) 2.7 (1.3) 2.4 (1.2)
  BASFI 3.0 (2.6) 3.0 (2.7) 2.8 (2.8)
  ASAS- HI 6.5 (4.6) 7.7 (5.1) 7.8 (4.6)
  Concomitant fibromyalgia* 736/3966 (18.6%) 33/130 (25.4%) 6/31 (19.4%)
All results are presented as mean and SD and percentages for continuous and categorical variables, respectively.
*Presence of Fibromyalgia defined by the fulfilment of the Fibromyalgia Rapid Screen Tool (FiRST).13
ASAS- HI, ASAS Health Index; ASDAS- CRP, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Disease Activity 
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rather than qualitative, suggesting that SpA constitutes 
one entity in which peripheral and axial manifestations 
coincides. This gives us the impression that rheumatolo-
gists worldwide consciously or subconsciously recognise 
these distributions on the basis of which they decide that 
a patient has SpA.
Two main clusters with regard to the location of 
peripheral musculoskeletal manifestations (ie, arthritis, 
enthesitis and dactylitis) were found: a ‘predominantly 
axial’ and a ‘predominantly peripheral’, which showed 
a high prevalence of clinical diagnosis of axSpA and PsA 
or pSpA, respectively. Typical features associated with 
axSpA were found in the ‘predominantly axial’ cluster: 
a higher prevalence of males, HLA- B27 positivity, axial 
involvement, uveitis and a lower prevalence of psoriasis; 
indeed, the diagnosis of axSpA was present in 67.5% of 
these patients. On the other hand, typical features asso-
ciated with the peripheral presentations of SpA (either 
pSpA or PsA) were found in the ‘predominantly periph-
eral’ cluster: a higher prevalence of females, HLA- B27 
negativity, a lower prevalence of axial involvement and a 
high prevalence of psoriasis, and a diagnosis of pSpA or 
PsA in these patients (11% and 61.3%, respectively). In 
addition, in this peripheral phenotype, 56.8% of patients 
fulfilled the CASPAR criteria, and only 25.8% fulfilled 
the ASAS peripheral criteria. The reason of this low prev-
alence of ASAS peripheral criteria resides in the fact that 
we can only apply these criteria in patients with current 
peripheral involvement and without current IBP,2 
making both ASAS peripheral and ASAS axial criteria 
mutually exclusive. Indeed, ignoring current IBP as an 
exclusion criterion for ASAS peripheral, we found that 
46.8% would fulfil these classification criteria, suggesting 
a high number of patients with predominantly periph-
eral symptoms in conjunction with IBP. This significant 
difference between the ‘strict’ and ‘non- strict’ ASAS 
peripheral criteria may be considered relevant enough 
to take into consideration for future adaptations of the 
current classification criteria.
Apart from these differences, both clusters also showed 
important overlaps. Both clusters (ie, ‘predominantly 
axial’ and ‘predominantly peripheral’) exhibited, to 
some extent, peripheral involvement, with the knee and 
the ankle among the most frequent joints affected in 
both groups, as well as heel enthesitis, confirming that 
differences in peripheral symptoms in SpA are rather 
quantitative than qualitative. These results are in line 
with a previous study using a latent class analysis (without 
preassumptions on the contribution of each SpA feature) 
that identified the clinical entity ‘axSpA with peripheral 
signs’, which included patients with concomitant IBP and 
peripheral features.15 However, in comparison with our 
study, patients from the ‘axSpA with peripheral signs’ 
showed a higher prevalence of ASAS peripheral criteria 
fulfilment. This is because authors applied the ASAS 
peripheral criteria in patients with IBP to better under-
stand the possible overlap between pSpA and axSpA with 
peripheral signs.
Our results also confirm the arthritis of the large joints of 
the lower limbs and the heel enthesitis as typical SpA mani-
festations in both the axial and peripheral phenotypes.16 A 
remarkable finding is the high proportion of patients from 
the peripheral phenotype showing upper limbs involvement, 
represented by arthritis of the wrists, metacarpophalangeal 
and proximal interphalangeal joints. Although upper limbs 
and small joints involvement is not a typical manifestation 
in patients with SpA, Moll and Wright described a polyartic-
ular subtype of PsA represented by arthritis of five or more 
symmetric joints resembling rheumatoid arthritis.16 17 Sixty- 
three per cent of patients from this peripheral phenotype 
suffered from psoriasis and 61.3% had a diagnosis of PsA, 
suggesting that rheumatologists recognise this pattern as 
suggestive of PsA.
The cluster analysis focusing on a specific clinical 
feature showed similar results, exhibiting a predomi-
nantly axial and a predominantly peripheral phenotype, 
but yielding three groups for each of the manifestation. In 
the analysis using information about the specific location 
of arthritis, hip involvement was especially noticed in the 
axial phenotype, confirming the association between this 
joint and axial disease18 . At variance, shoulder involve-
ment was not especially noteworthy in the axial but was 
more predominant in the peripheral phenotype; in addi-
tion, in the MCA analysis, we found a strong association 
of this location with the knee and ankle, suggesting that, 
as opposed to the hip, the shoulder behaves mostly as a 
peripheral rather than an axial joint.
The results from the cluster analysis of enthesitis 
showed three clusters, with two of them resembled 
the axial phenotype: a ‘pure’ axial disease with axial 
involvement and heel enthesitis as the major clinical 
presentation, and a second cluster with predominantly 
axial enthesitis (eg, nuchal crests, thoracic and lumbar 
spinous processes, iliac tuberosities…). In fact, in both 
of these clusters, the most frequent diagnosis according 
to the rheumatologist was axSpA (61.4% and 64.1%, 
respectively). With regard to the enthesitis, a third cluster 
resembling a peripheral phenotype was found, which was 
associated more frequently with psoriasis. This group 
with peripheral polyenthesitis exhibited a higher preva-
lence of fibromyalgia according to the FiRST question-
naire in comparison with the clusters resembling axial 
phenotypes. However, whether these patients suffered 
from a true inflammatory polyenthesitis or a concomi-
tant fibromyalgia cannot be distinguished in this study.
This study has some limitations and some strengths. One 
major limitation is the difficulty of correctly evaluating 
peripheral involvement that occurred before the study visit, 
which may be hampered by recall bias, especially in patients 
with a long- standing disease. Another limitation is the cross- 
sectional nature of the study, which precludes the evaluation 
of the cluster evolution over time. The main strength of this 
study is the large sample size and the number of partici-
pating countries providing a worldwide representation of 
patients from the whole spectrum of SpA and PsA. In fact, 
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across regions was found, which justify the pooling analysis 
of the data (online supplemental table S1).
In summary, these results distinguish two main pheno-
types (a predominantly axial and a predominantly 
peripheral phenotype) on the basis of the peripheral mani-
festations, which fitted a clinical diagnosis of axSpA and 
pSpA (including PsA), respectively. This study does not only 
suggest that clinicians include peripheral manifestations in 
their assessment of whether a patient has axial or peripheral 
SpA; it also emphasises several other interesting elements, 
such a close association between heel enthesitis and axial 
SpA and a difference between root joints (eg, shoulder is 
more related with the peripheral phenotype while hip is 
more related with the axial one). Thus, the often- artificial 
difference between axial and peripheral SpA therefore 
continues to make sense, although whether PsA can be 
considered part of SpA or as a separate entity cannot be 
answered with this study. However, an important overlap 
of peripheral manifestations was found across the different 
underlying entities. These results also confirm the variability 
of making a diagnosis by rheumatologists depending on the 
presence of peripheral manifestations.
Future prospective studies would be useful to assess 
the changes in phenotypes over time, and molecular and 
genetic studies are needed to evaluate whether these clinical 
phenotypes are genetically similar or different.
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